Developing differentiated medicines

for devastating diseases including intractable cancers, lymphatic and GI diseases, CNS disorders and inflammatory and immunological diseases

Focus on the Brain Immune Gut (BIG) Axis

24 products and product candidates

13 are clinical stage

2 granted FDA clearance

Relationships with multiple major pharma companies or their investment arms

Team of world-class scientists and industry leaders


PureTech's Components of Value

 

Learn more about our unique discovery process

Wholly Owned Pipeline

Our programs
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
LYT-100
Deupirfenidone
Lymphatic flow disorders, incl. lymphedema
Readout from Phase 1 MAD study & initiation of POC study in H2 2020
LYT-100
Deupirfenidone
Serious respiratory complications after COVID-19
Initiation of Phase 2 study in H2 2020
LYT-100
Deupirfenidone
Other fibrotic & inflammatory disorders, such as IPF
LYT-200
Anti-Galectin-9 MAb
Solid tumors
IND and initiation of Phase 1 study in 2020
LYT-210
Anti-Delta-1 MAb
Solid tumors
LYT-300
Oral Allopregnanolone
Neurological indications

Cash at Puretech Parent Level

Founded Entities

1. Funding figure includes private equity financings, public offerings or grant awards. Funding figure excludes upfront payments and future milestone considerations received in conjunction with partnerships and collaborations such as those with Roche, Boehringer Ingelheim, Imbrium Therapeutics L.P., Shionogi & Co., Ltd. or Eli Lilly.

2. At the parent level, PureTech Health plc had cash and cash equivalents of $310.5 million at June 30, 2020, which does not reflect $101.6 million in proceeds received by PureTech in August 2020 from the sale of 1.3 million shares of Karuna common stock and excludes all other cash outflows from June 30, 2020, for total adjusted cash and cash equivalents of $412.1 million as of August 26, 2020.

3. PureTech Level Cash Reserves at June 30, 2020 represent cash balances and short-term investments held at PureTech Health LLC, PureTech Management, Inc., PureTech Health PLC, PureTech Securities Corporation of $284.2 million and held at PureTech LYT Inc., our internal pipeline, of $26.3 million, all of which are wholly owned entities of PureTech, excluding cash balances and short-term investments of Controlled Founded Entities which are not wholly owned.

Publications
Internal Pipeline
PureTech's Lymphatic Leap
Gamma Delta T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation

CD4(+) T regulatory cells (T(regs)), which express the Foxp3 transcription factor, play a critical role in the maintenance of immune homeostasis. Here, we show that in mice, T(regs) were most abundant in the colonic mucosa.

Full Article

Vedanta
Science: The Gut’s Clostridium Cocktail
Press releases
2020-10-21
PureTech Founded Entity Akili Announces Presentation of New Outcome Data for Digital Therapeutic EndeavorRx™ in Paediatric ADHD

Continue

Press releases
2020-10-20
PureTech Founded Entity Vor Biopharma Appoints Matthew R Patterson to its Board of Directors

Continue

Press releases
2020-10-12
PureTech Founded Entity Vedanta Biosciences Announces Additional Pharmacokinetics Data from Phase 1 Study of VE202 for Inflammatory Bowel Disease to be Presented at United European Gastroenterology Week 2020

Continue